Apolipoprotein E allele 4 is not a sufficient or a necessary predictor of the development of Mild Cognitive

R Heun1, U Gühne, T Luck

  • 1Department of Psychiatry, Derby City General Hospital, Uttoxeter Road, Derby 22, UK. heun@gmx.com

Insights

The apolipoprotein E (apoE) varepsilon4 allele does not predict the development of Mild Cognitive Impairment (MCI). This finding suggests apoE varepsilon4 is not a necessary or sufficient risk factor for MCI.

Area of Science:

  • Neuroscience
  • Genetics
  • Epidemiology

Background:

  • Mild Cognitive Impairment (MCI) precedes Alzheimer's disease.
  • The apolipoprotein E (apoE) varepsilon4 allele is a known risk factor for Alzheimer's disease.
  • The role of apoE varepsilon4 in the development of MCI is not well understood.

Purpose of the Study:

  • To investigate the prevalence of the apoE varepsilon4 allele in individuals with incipient Mild Cognitive Impairment (MCI).

Main Methods:

  • Population-based cohort study (Leipzig Longitudinal Study of the Aged, LEILA75+).
  • Follow-up of initially cognitively healthy individuals for 4.5 years.
  • Genotyping for apoE varepsilon4 status and assessment of MCI criteria.

Main Results:

  • 15.5% of the initially healthy population developed MCI over 4.5 years.
  • The frequency of the apoE varepsilon4 genotype did not differ between individuals who developed MCI (12.9%) and those who remained cognitively healthy (18.4%).
  • p-value > 0.5 indicates no statistically significant difference.

Conclusions:

  • The apoE varepsilon4 genotype is neither a necessary nor a sufficient risk factor for the development of MCI.
  • Further research is needed on combined genetic and environmental factors influencing MCI and Alzheimer's disease progression.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...